Sodium-glucose cotransporter 2 (SGLT2) inhibitors, initially developed as anti-hyperglycemic drugs, have been shown to significantly improve metabolic indicators and protect the kidneys and hearts of patients with and without type 2 diabetes. The possible mechanisms for these benefits are the subject of extensive research, as they cannot be attributed solely to improved blood sugar control. In this book, we will focus on the current understanding of cardio-renal protection by SGLT2 inhibitors by explaining the pathophysiological mechanisms involved, and we will present the largest trials that have demonstrated this organoprotective effect.